Dupilumab reduces tissue eosinophils in nasal polyps beyond improving clinical and endoscopic outcomes. Dupilumab treatment is associated with a reduction of tissue inflammatory eosinophils that correlates with higher clinical and endoscopic improvement.
Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Patients: Impact on Tissue Eosinophilic Inflammation and Eosinophil Subphenotypes / Vultaggio, A., Accinno, M., Vivarelli, E., Milanese, M.E., Diomaiuti, M., Illiano, G., Orlando, P., Palomba, A., Ammatuna, C., Cosmi, L., Rossi, O., Maggi, E., Maggiore, G., Matucci, A.. - In: CLINICAL AND EXPERIMENTAL ALLERGY. - ISSN 0954-7894. - ELETTRONICO. - (2026), pp. 1-3. [10.1111/cea.70309]
Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Patients: Impact on Tissue Eosinophilic Inflammation and Eosinophil Subphenotypes
Vultaggio, Alessandra;Accinno, Matteo;Vivarelli, Emanuele;Milanese, Maria Elena;Diomaiuti, Michael;Illiano, Gennaro;Orlando, Pietro;Palomba, Annarita;Ammatuna, Carlo;Cosmi, Lorenzo;Rossi, Oliviero;Maggi, Enrico;Maggiore, Giandomenico;Matucci, Andrea
2026
Abstract
Dupilumab reduces tissue eosinophils in nasal polyps beyond improving clinical and endoscopic outcomes. Dupilumab treatment is associated with a reduction of tissue inflammatory eosinophils that correlates with higher clinical and endoscopic improvement.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Clin Experimental Allergy - 2026 - Vultaggio - Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Patients Impact on.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
222.14 kB
Formato
Adobe PDF
|
222.14 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
